title: An interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute. Interviewed by Vicki Glaser.
authors.forename: Doriano
authors.initials: D
authors.lastname: Fabbro
mesh_terms: D001549:Benzamides; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D000068877:Imatinib Mesylate; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D047908:Intracellular Signaling Peptides and Proteins; D010879:Piperazines; D011743:Pyrimidines; C015482:protein kinase modulator; D000068877:Imatinib Mesylate